Compare Abeona Therapeutics Inc (ABEO) vs Manchester United PLC (MANU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Manchester United PLC — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Manchester United PLC trades at $21.87 (market cap $3.85B). The key difference: Manchester United PLC is far larger — about 10.3× Abeona Therapeutics Inc's market cap, and Manchester United PLC pays a 1.26% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MANU | |
|---|---|---|
Market Cap | $373.32M | $3.85B |
Sector | Health | Media |
52-Week High | $7.23 | $23.53 |
52-Week Low | $4.17 | $15.10 |
Enterprise Value | $228.22M | $4.77B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Manchester United (MANU) trades at $22.35, down 3.29% on the day, with a bullish technical outlook from moving averages but mixed oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, while revenue trends show modest growth to $667M in 2025. Recent news highlights stadium expansion plans and Champions League qualification as positive catalysts, though profitability remains challenged with a net income margin of -4.96% in 2025.
The outlook is cautiously optimistic with analyst consensus leaning hold (60%) amid valuation concerns (P/S 4.25, P/B 16.21). Key opportunities include revenue upside from new stadium and European competition, while risks involve persistent losses, high debt, and sports performance volatility. The stock's proximity to its 52-week high of $24.22 suggests limited near-term upside without fundamental improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
